116 related articles for article (PubMed ID: 9744338)
1. Technetium-99m-furifosmin in the follow-up of differentiated thyroid carcinoma.
Brandt-Mainz K; Müller SP; Sonnenschein W; Bockisch A
J Nucl Med; 1998 Sep; 39(9):1536-41. PubMed ID: 9744338
[TBL] [Abstract][Full Text] [Related]
2. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
3. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
4. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography.
Wu YJ; Wu HS; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(3C):2973-6. PubMed ID: 12926147
[TBL] [Abstract][Full Text] [Related]
5. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
[TBL] [Abstract][Full Text] [Related]
6. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
7. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A
Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773
[TBL] [Abstract][Full Text] [Related]
8. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
10. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.
Sathekge M; Maes A; D'Asseler Y; Vorster M; Van de Wiele C
Nucl Med Commun; 2012 Jun; 33(6):581-90. PubMed ID: 22422098
[TBL] [Abstract][Full Text] [Related]
11. The usefulness of 99mTc-tetrofosmin SPECT in the detection of lung metastases from extrapulmonary primary tumors.
Spanu A; Solinas ME; Farris A; Arru A; Chessa F; Madeddu G; Falchi A; Madeddu G
Radiol Med; 2004; 107(1-2):113-27. PubMed ID: 15031703
[TBL] [Abstract][Full Text] [Related]
12. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG.
Cook GJ; Houston S; Barrington SF; Fogelman I
J Nucl Med; 1998 Jan; 39(1):99-103. PubMed ID: 9443745
[TBL] [Abstract][Full Text] [Related]
13. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
Alnafisi NS; Driedger AA; Coates G; Moote DJ; Raphael SJ
J Nucl Med; 2000 Jun; 41(6):1010-5. PubMed ID: 10855626
[TBL] [Abstract][Full Text] [Related]
14. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
15. Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma.
Chen YK; Liu FY; Yen RF; Kao CH
Acad Radiol; 2003 Aug; 10(8):835-9. PubMed ID: 12945916
[TBL] [Abstract][Full Text] [Related]
16. Use of 99mTc-furifosmin scintigraphy--planar and SPECT--to evaluate suggestive palpable and nonpalpable breast lesions.
Obwegeser R; Berghammer P; Rodrigues M; Kubista E; Sinzinger H
J Nucl Med; 2000 Mar; 41(3):426-8. PubMed ID: 10716314
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
[TBL] [Abstract][Full Text] [Related]
19. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
20. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide.
Scott GC; Meier DA; Dickinson CZ
J Nucl Med; 1995 Oct; 36(10):1843-5. PubMed ID: 7562053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]